» Articles » PMID: 6832932

Monoclonal Antibody Radioimmunodetection of Human-derived Colon Cancer

Overview
Journal Invest Radiol
Specialty Radiology
Date 1983 Jan 1
PMID 6832932
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

This study was designed to determine whether monoclonal antibody directed against carcinoembryonic antigen could successfully be used in the scintigraphic localization of a human-derived colon carcinoma in a hamster model. An immunoglobulin G (IgG)-1 kappa monoclonal antibody, prepared in this laboratory, against carcinoembryonic antigen (CEA) was radiolabeled with iodine-131 (131I). Four Syrian hamsters bearing GW-39 human colon cancers received intracardiac injections of 50 mu Ci of 131I (14 micrograms of antibody). Gamma camera images were obtained at 24-hour intervals. Animals were sacrificed at 11 days, and the tumors and entire animals were counted. A double-label antibody experiment was conducted with 131I anti-CEA and nonspecific MOPC 21 IgG iodine-125 (125I) to assess localization specificity. The scintiphotos clearly showed the tumor at 24 hours, but there was significant background (blood-pool activity). Later images at six and 11 days showed a gradual decrease in background activity and more clear definition of the tumor. Animals sacrificed at 11 days showed 48-80% of residual whole body radioactivity to be present in the tumor. However, these tumors were large at sacrifice, weighing 8.9 to 12.4 g. Specific localization was confirmed by the double-label experiments where specific localization was twice nonspecific accretion of IgG in the tumor. This study has shown that a specific monoclonal antibody can successfully be used to scintigraphically localize a colon tumor of human origin. Although clearance of background activity is a gradual process, eventually most radioactivity left in the animal is localized in the tumor. This study illustrates that the potential radiolabeled monoclonal antibodies hold as immunodiagnostic agents.

Citing Articles

The Prognostic and therapeutic value and clinical implications of fibroblast activation protein-α as a novel biomarker in colorectal cancer.

Kalaei Z, Manafi-Farid R, Rashidi B, Kiani F, Zarei A, Fathi M Cell Commun Signal. 2023; 21(1):139.

PMID: 37316886 PMC: 10265921. DOI: 10.1186/s12964-023-01151-y.


A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer.

Wang H, Meng A, Li S, Zhou X Mol Med Rep. 2017; 16(1):625-630.

PMID: 28586008 PMC: 5482067. DOI: 10.3892/mmr.2017.6677.


Receptor imaging of pediatric tumors: clinical practice and new developments.

Daldrup-Link H, Hawkins R, Meier R, Goldsby R, Artemov D Pediatr Radiol. 2008; 38(11):1154-61.

PMID: 18483730 DOI: 10.1007/s00247-008-0878-x.


Rapid prototyping techniques for anatomical modelling in medicine.

McGurk M, Amis A, Potamianos P, Goodger N Ann R Coll Surg Engl. 1997; 79(3):169-74.

PMID: 9196336 PMC: 2502901.


The effect of specimen processing on radiolabeled monoclonal antibody biodistribution.

Wahl R, Sherman P, Fisher S Eur J Nucl Med. 1984; 9(8):382-4.

PMID: 6489371 DOI: 10.1007/BF00252876.